Clinical Report: Prognostic Factors and Survival in Primary Liver Cancer Patients

Overview

This study evaluates prognostic factors affecting overall survival in primary liver cancer patients treated with transarterial chemoembolization (TACE). A Cox-based prediction model was developed, demonstrating good discrimination and identifying key independent predictors of survival.

Background

Primary liver cancer, particularly hepatocellular carcinoma (HCC), is a leading cause of cancer mortality globally. TACE is a standard treatment for unresectable HCC, yet patient outcomes vary significantly due to factors such as tumor burden and liver function. Understanding these prognostic factors is crucial for optimizing treatment strategies and improving patient survival.

Data Highlights

Key Findings

• Median overall survival (OS) was 28.0 months with a 12-month OS rate of 76.4%.
• Independent predictors of worse OS included maximum tumor diameter, portal vein tumor thrombosis, and Child–Pugh class B.
• The model showed good discrimination with a C-index of 0.812 in training and 0.791 in validation.
• Objective response rate (ORR) was 48.1% with a disease control rate (DCR) of 73.5% based on mRECIST.
• Alpha-fetoprotein (AFP) levels were significant predictors of survival, with HR of 1.946 per 1 log10 increase.

Clinical Implications

Clinicians should consider the identified prognostic factors when evaluating patients for TACE to tailor treatment plans effectively. The developed prediction model can assist in risk stratification and guide clinical decision-making regarding patient management and follow-up.

Conclusion

The study provides a robust model for predicting survival in primary liver cancer patients undergoing TACE, emphasizing the importance of integrating clinical and biological factors in treatment planning.

Related Resources & Content

1. European Radiology, 2024 -- Machine Learning-Based Assessment of Prognosis and Risk Stratification for Unresectable Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Intra-arterial Chemotherapy
2. Frontiers in Medicine, 2026 -- Prediction of the efficacy after the first transarterial chemoembolization in hepatocellular carcinoma using CT radiomics combined with inflammatory composite indicators
3. Frontiers in Medicine, 2026 -- The benefit and risk of adding PD-1/PD-L1 inhibitors plus anti-VEGF drugs to transarterial chemoembolisation for unresectable, non-metastatic hepatocellular carcinoma: a pooled analysis of four RCTs
4. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma, 2025
5. Frontiers in Oncology — Prognostic model for predicting recurrence-free survival in HBV-related hepatocellular carcinoma patients after combined treatment: a multicenter study
6. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
7. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial - PubMed